DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for learning disability — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLearning disability maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for learning disability is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
One hundred and thirty-six patients with learning disability were discharged from a long-stay hospital to the community and registered with 21 general practices. The additional workload and prescribing costs for these patients were compared with age- and sex-matched controls from the same practices. Only three of the 21 practices carried out the six-monthly health and medication reviews that general practitioners had agreed should be standard good practice primary healthcare for people with learning disability.
The Montgomery judgment of 2015 introduced a new definition of informed consent that applies to all healthcare professionals, including pharmacists. For patients with learning disability, the Accessible Information Standard, in force in England since August 2016, must also be considered. Easy-read material must be of a standard and quality relevant to the particular individual. The article also briefly considers whether information should always be disclosed.
Approximately four to six percent of Canadian children and youth have a learning disability. Three well-explored categories are dyslexia, dyscalculia, and dysgraphia. Treatment and management options are divided into compensatory strategies and remedial treatments, including drilling and practice, task analysis, computer aids, faded support, and multisensory instruction. Community supports are also available. The COVID-19 pandemic changed the accessibility of education and impacted the health of children and youth with learning disabilities. Despite developments, gaps and critiques persist in the research.
Learning disability is a paediatric disorder of reading, writing or arithmetic skills. When it is not secondary to known diseases such as autism, epilepsy or genetic pathologies, it causes diagnostic difficulties. In Italy, where diagnosis can involve the provision of economic benefits, available diagnostic instruments should be sensitive and specific to win the risk of symptom simulation. A greater interest of research in this field is desirable. What is still missing is evidence from properly funded trials that test specific remedial or compensatory strategies against placebo or standard care, and diagnostic tools validated against objective outcomes rather than benefit eligibility.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Learning Disabilities · 1998 · 20 citations
The Primary Care Workload and Prescribing Costs Associated with Patients with Learning Disability Discharged from Long‐stay Care to the Community
AbstractOne‐hundred‐and‐thirty‐six patients with learning disability were discharged from a long‐stay hospital to the community, and were registered with a total of 21 practices. This study estimated the additional general practice workload and prescribing costs incurred by the transferred patients, compared with age/sex matched controls from the same practices. The workload was recorded prospectively. General practitioners agreed that six‐monthly health checks and medication reviews should be standard good practice primary healthcare for those with learning disability. Only three practices undertook proactive six‐monthly health and medication reviews of all study patients.
The implications of the Montgomery judgment on pharmacy practice and patients with learning disability
AbstractThe judgment in Montgomery v Lanarkshire (Scotland) 2015 introduced a new definition of informed consent which has implications for all healthcare professionals. This article focuses specifically on the implications for pharmacy practice and patients with learning disability. During consultations, both pharmacist prescribers and non-prescribing pharmacists must adhere to the provisions of the judgment to ensure patients provide informed consent. Particular issues arise where patients with learning disability are concerned because the Accessible Information Standard (AIS), which came into force in England in August 2016, must also be considered. Consequently, easy-read material should also be of a standard and quality relevant to that particular individual. In addition, this article will briefly consider whether information should always be disclosed.
The Child Health Interdisciplinary Literature and Discovery Journal · 2022 · 0 citations · open access
Review: An Inquiry into Current Treatment and Management Strategies for Children with Learning Disabilities
AbstractCurrently, approximately four to six percent of all Canadian children and youth have a learning disability. Three well-explored categories of learning disabilities are dyslexia, dyscalculia, and dysgraphia. Learning disabilities can affect all aspects of a youth’s life and development, including social-emotional, cognitive, physical, and behavioural-moral domains. Options to treat and manage learning disabilities are currently divided into compensatory strategies and remedial treatments, including drilling and practice, task analysis, computer aids, faded support, and multisensory instruction. Different types of community-supports are also available to supplement treatment and management options. As a newly recognized field, research on learning disabilities has seen major developments within the last few decades, with significant changes during the COVID-19 pandemic. COVID-19 has impacted the health of children and youth with learning disabilities and changed the accessibility of education. However, despite the developments in the field, gaps and critiques persist in the research. This paper aims to review the current literature on treatments, community supports, and management strategies for learning disabilities in Canada and discuss the impacts of COVID-19. Reviewing existing data and gaps in the literature will help provide a holistic overview of the current state of the literature on learning disabilities in children and youth in Canada.
International Journal of Neurology and Brain Disorders · 2014 · 0 citations · open access
Learning Disability and Medico-Legal Implications
AbstractLearning Disability is a pediatric disorder of reading, writing or arithmetic skills. When it's no secondary to known diseases (called Not Otherwise Specified) as autism, epilepsy or genetic pathologies, it causes many diagnostic difficulties. Especially if as in Italy the diagnosis involves the provision of benefits, also economic benefits. The available diagnostic instruments should have a sensible and specific diagnostic to win the simulation risk of siymptomps and for this reason a greater interest of research in this field is desiderable.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
